Journal of Gastroenterology

, Volume 31, Issue 6, pp 806–811

Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: Relation to effectiveness of interferon therapy

  • Ryo Fukuda
  • Norihisa Ishimura
  • Shunji Ishihara
  • Alejandro Tokuda
  • Shuichi Satoh
  • Shino Sakai
  • Shuji Akagi
  • Makoto Watanabe
  • Shiro Fukumoto
Liver, Pancreas, and Biliary Tract


To investigate whether interferon-alpha receptor (IFN-αRc) expression was related to the effectiveness of interferon therapy in hepatitis C virus (HCV)-associated chronic liver disease (CLD), IFN-αRc mRNA was investigated by reverse transcription polymerase chain reaction (RT-PCR) in liver biopsies and peripheral blood mononuclear cells (PBMCs) from 40 patients with HCV-associated CLD who subsequently received IFN-α therapy. IFN-αRc mRNA in the liver was detected in 18 of 20 (90%) responders to IFN and in 5 of 20 (25%) non-responders (P<0.01). In PBMCs, IFN-αRc mRNA was detected in all patients regardless of response to IFN. Increased histological hepatitis activity and liver fibrosis were significantly related to the absence of IFN-αRc mRNA. The HCV-RNA genotype showed no significant relationship to IFN-αRc mRNA expression. Our results suggest that IFN-αRc mRNA expression in the liver, but not in PBMCs, is closely associated with the effectiveness of IFN-α therapy in HCV-associated CLD.

Key words

Chronic hepatitis C interferon-α receptor mRNA interferon therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Magrin S, Graxi A, Fabiano C, et al. Serum hepatitis C virus (HCV)-RNA and response to alpha interferon in anti-HCV positive chronic hepatitis. J Med Virol 1992;38:200–206.PubMedGoogle Scholar
  2. 2.
    Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121–1130.CrossRefPubMedGoogle Scholar
  3. 3.
    Yoshida K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha: Relationship to genotype of hepatitis C virus. Hepatology 1992;14:35–40.Google Scholar
  4. 4.
    Weiland O, Schvarcz R, Weijstal R, et al. Therapy of chronic posttransfusion non-A non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990;11(Suppl 19):S57-S62.PubMedGoogle Scholar
  5. 5.
    Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088–1094.CrossRefPubMedGoogle Scholar
  6. 6.
    Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Yonehara S, Yonehara-Takahashi M, Ishii A. Binding of human interferon alpha to cells of different sensitivities: Studies with internally radiolabeled interferon retaining full biological activity. J Virol 1983;45:1168–1171.PubMedGoogle Scholar
  8. 8.
    Zoon KC, Arnheimer H. Studies of the interferon receptors. Pharmacol Ther 1984;24:259–278.CrossRefPubMedGoogle Scholar
  9. 9.
    Kato T, Esumi M, Yamashita S, et al. Interferon-inducible gene expression in chimpanzee liver infected with hepatitis C virus. Virology 1992;190:856–860.CrossRefPubMedGoogle Scholar
  10. 10.
    Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein kinase in the interferon alpha/beta signaling pathway. Cell 1992;24:313–322.Google Scholar
  11. 11.
    De Maeyer E, De Maeyer-Guignand J. Interferon receptor. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley and Sons, 1988;91–113.Google Scholar
  12. 12.
    Lau AS, Hanningan GE, Freedman MH, Williams BRG. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest 1986; 77:1632–1638.PubMedGoogle Scholar
  13. 13.
    Gallo-Rayet N, Escher E. Adrenocorticotropin receptors in rat adrenal glomerulosa cells. Endocrinology 1985;117:38–46.Google Scholar
  14. 14.
    Merlin G, Falcoff E, Aguet M.125I-labeled human interferon alpha beta and gamma: Comparative receptor-binding data. J Gen Virol 1985;66:1149–1152.PubMedGoogle Scholar
  15. 15.
    Aguet M, Grobke M, Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: Their binding affinities correlate with their specific biological activities. Virology 1984;132:211–216.CrossRefPubMedGoogle Scholar
  16. 16.
    De Maeyer E, De Maeyer-Guignand J. Production of IFN-γ by T cells and modulation of T cell, B cell, and NK cell activity by interferons. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley and Sons, 1988;221–273.Google Scholar
  17. 17.
    Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: Cloning and expression of its cDNA. Cell 1990;60:225–234.PubMedGoogle Scholar
  18. 18.
    Ishimura N, Fukuda R, Fukumoto S. Relationship between the expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases. J Gastroenterol Hepatol 1996;11:712–717.PubMedGoogle Scholar
  19. 19.
    Karino Y, Hige S, Sasaki Y, Tsuyuguchi M, Matsushima T, Miyazaki T, Okuuchi Y, Toyota J. Relationship between serum 2-5AS activity and the reduction of HCV-RNA during interferon therapy. In: Nishioka K, Suzuki H, Mishiro S, Oda K (eds). Viral hepatitis and liver disease. Tokyo New York Berlin Heidelberg: Springer, 1994;631–634.Google Scholar
  20. 20.
    Fukuda R, Satoh S, Nguyen TX, et al. Expression of cytokine mRNA in the liver of chronic hepatitis C: Comparison with chronic hepatitis B. J Gastroenterol 1995;31:41–47.Google Scholar
  21. 21.
    Okamoto H, Sugiyama Y, Okada S, et al. Typing of hepatitis C virus by polymerase chain reaction with type specific primers; application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673–679.PubMedGoogle Scholar
  22. 22.
    Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993;104:877–883.PubMedGoogle Scholar
  23. 23.
    Degroote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968;II:626–628.Google Scholar
  24. 24.
    Knodell RG, Isak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431–435.PubMedGoogle Scholar
  25. 25.
    De Maeyer E, De Maeyer-Guignand J. The antiviral activity of interferon. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley, Sons, 1988;115–133.Google Scholar
  26. 26.
    Su L, Morgan PR, Harrison DL, Waseen A, Lane EB. Expression of keratin mRNAs and proteins in normal salivary epithelia and pleomorphic adenomas. J Pathol 1993;171:173–181.CrossRefPubMedGoogle Scholar
  27. 27.
    Greenway AL, Hertzog PJ, Devenish RJ, et al. Immunolocalisation of interferon-alpha in hepatitis C patients and its correlation with response to interferon-alpha therapy. J Hepatol 1994;21:842–852.CrossRefPubMedGoogle Scholar
  28. 28.
    Müller U, Steihoff U, Reis LF, et al. Functional roles of type I and type II interferons in antiviral defense. Science 1994;264:1918–1921.PubMedGoogle Scholar
  29. 29.
    Branca AA, Bagloni C. Down-regulation of the interferon receptor. J Biol Chem 1982;257:13197–13200.PubMedGoogle Scholar
  30. 30.
    Evans T, Secher DD. Kinetics of internalization and degradation of surface-bound interferon in human lymphoblastoid cells. EMBO J 1984;3:2975–2978.PubMedGoogle Scholar
  31. 31.
    Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: Characterization and molecular cloning. Cell 1994; 77:391–400.CrossRefPubMedGoogle Scholar
  32. 32.
    Affabris E, Romeo G, Belardelli F, et al. 2-5A synthetase activity does not increase in interferon-resistant Friend leukemia cell variants treated with α/β interferon despite the presence of high-affinity interferon receptor sites. Virology 1983;125:508–512.CrossRefPubMedGoogle Scholar
  33. 33.
    Auguet M, Gresser I, Hovanessian AG, et al. Specific high-affinity binding of125I-labeled mouse interferon to interferon-resistant embryonal carcinoma cells in vitro. Virology 1981;114:585–588.Google Scholar
  34. 34.
    Klippel JH, Carrete S, Preble S, et al. Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus. Ann Rheum Dis 1985;44:104–108.PubMedGoogle Scholar
  35. 35.
    Koziel MJ, Duddley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339–3344.PubMedGoogle Scholar
  36. 36.
    Kita H, Moriyama T, Kaneko T, et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993;18:1039–1044.CrossRefPubMedGoogle Scholar
  37. 37.
    Lörh HF, Schlaak JF, Gerken G, et al. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994;14:161–166.Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Ryo Fukuda
    • 1
  • Norihisa Ishimura
    • 1
  • Shunji Ishihara
    • 1
  • Alejandro Tokuda
    • 1
  • Shuichi Satoh
    • 1
  • Shino Sakai
    • 1
  • Shuji Akagi
    • 1
  • Makoto Watanabe
    • 1
  • Shiro Fukumoto
    • 1
  1. 1.Second Department of Internal MedicineShimane Medical UniversityShimaneJapan

Personalised recommendations